Zydus Cadila has signed a drug development and commercialisation pact with Germany-based Pieris AG to develop a new therapeutic protein molecule — Anticalin.
The collaboration combines Pieris’ drug discovery and early development capabilities with Zydus’ expertise in biologics development, regulatory affairs and biologics manufacturing, Zydus said.
“Under the terms of agreement, Zydus will take the lead in advancing Anticalin drug candidates through preclinical development and into clinincal development...” it added.
Zydus has been granted exclusive marketing rights in India and several other emerging markets, while Pieris retains exclusive marketing rights in key developed markets.
“Collaborating with established biotech companies on differentiated drug candidates is an important component of Zydus' ongoing transformation into an innovation-led global healthcare provider and we are pleased to add Anticalin to our novel biologics pipeline,” said R Patel, CMD, Zydus Group.
The two companies said the most advanced programme in their collaboration is PRS-110, a target, which is increasingly becoming validated across a broad spectrum of tumours.
“This collaboration will allow Pieris to unlock value on a global scale on a cost-effective manner, significantly expanding the number of proprietary Anticalin programmes we can advance into clinical trials,” said Stephen Yoder, CEO, Pieris.
Through the collaboration, the companies seek to develop candidates to proof-of-concept and will explore out-licensing opportunities in Pieris’ territories.
“The companies will share licensing revenues on mutually agreed upon terms,” it added.